TICKERNERD
Menu
FEMYFEMYHealthcare · Medical Instruments & Supplies

FEMY Stock Forecast: Femasys, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$2.59
+1.57% on the day

The 3 Wall Street analysts covering Femasys, Inc. hold a median 12-month price target of $10 — +286.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 19 Sept 2026 — in the lower half.

Market cap
$21.7M
Ticker Nerd rank
43 / 100
Median analyst target
$10
Analysts covering
3
Revenue$332K−18.9% y/y
Operating income−$5.1M
Net income−$4.5M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.8%
1M
+17.7%
YTD
−77.5%
1Y
−64.0%
From 52W high
−87.5%
From 52W low
+19.9%
$2
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FEMY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Femasys, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Size
88
Revisions
64
Issuance
62
Volatility
52
Accruals
27
Momentum
24
Quality
13
Value
12

Growth (98): Sales and profits are climbing, and climbing faster than before.

Value (12): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FEMY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FEMY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26FEMYHigh $23Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $10Median $10High $23

The green dot is the last close — the median target sits +286.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026Lake StreetMaintainsBuy$30 → $10
14 Aug 2026Maxim GroupMaintainsBuy$30 → $10
3 Mar 2026Lake StreetInitiatesBuy$1.50
3 Mar 2026Lake StreetInitiatesBuy—
20 Nov 2025Laidlaw & Co.InitiatesBuy—
11 Aug 2025HC Wainwright & Co.MaintainsBuy—
25 June 2025HC Wainwright & Co.ReiteratesBuy—
11 June 2025HC Wainwright & Co.ReiteratesBuy—
13 May 2025Jones TradingMaintainsBuy—
9 May 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.MaintainsBuy—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
26 Feb 2025HC Wainwright & Co.ReiteratesBuy—
11 Feb 2025HC Wainwright & Co.ReiteratesBuy—
3 Dec 2024HC Wainwright & Co.ReiteratesBuy—
27 Nov 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024Chardan CapitalMaintainsBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FEMY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FEMY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Femasys, Inc. returned −64.0% against +16.3% for the S&P 500, dividends included.

FEMY vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250300Oct 25Jan 26Apr 26Jul 26FEMYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FEMY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Femasys, Inc. (FEMY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 78% of US stocks

Price / sales
9.4×

Cheaper than 15% of US stocks

Price / book
1.9×

Cheaper than 46% of US stocks

EV / EBITDA
−1.5×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−18.9%

Higher than 12% of US stocks

Earnings growth (YoY)
−18.9%

Higher than 21% of US stocks

Gross margin
57.1%

Higher than 70% of US stocks

Operating margin
−1526.7%

Higher than 5% of US stocks

Net margin
62.0%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−425.0%

Higher than 4% of US stocks

Return on assets
−84.2%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Femasys, Inc. (FEMY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Femasys, Inc. has a market value of $21.7M and an enterprise value of $25.0M.

  • Revenue in the twelve months to 30 June 2026: $2.3M. The latest quarter shrank 18.9% year on year.

  • Net income over the same four quarters: −$11.8M, a −511.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$18.2M.

  • Shares outstanding: 3.0M.

  • Trailing P/E: −0.3×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Femasys, Inc. employs 51 people — $45K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

FEMY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
FEMYFemasys, Inc.$21.7M
43
RVPRetractable Technologies, Inc.$21.5M
60
BNGOBionano Genomics, Inc.$20.4M
78
HBIOHarvard Bioscience, Inc.$35.6M
98
MLSSMilestone Scientific, Inc.$35.9M
85
RGNTRegentis Biomaterials Ltd.$12.7M
8
NEPHNephros, Inc.$45.8M
93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Femasys, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FEMY news & analysis

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's Care

GlobeNewsWire · 15 Sept 2026positive

Femasys announced that Minnesota Women's Care will adopt its FemaSeed Complete portfolio and FemVue technology for fertility diagnostic evaluation and in-office first-line fertility treatment across its four OB/GYN practice locations. This marks an advancement in the company's expansion within the OB/GYN market.

Why it matters — A multi-site OB/GYN practice adopting FemVue and FemaSeed across all its locations signals growing commercial uptake of Femasys' fertility products in the clinical market.

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

GlobeNewsWire · 9 Sept 2026positive

Femasys announced a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio through dedicated financing solutions. The company described this as a step toward improving standards of care and expanding access to its products.

Why it matters — The partnership could broaden patient access to Femasys' fertility products through financing options, potentially supporting adoption of its FemaSeed portfolio.

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

GlobeNewsWire · 26 Aug 2026positive

Femasys announced a partnership with UNC Health to introduce its fertility portfolio—FemVue, SpermVue, and FemaSeed Complete—into UNC Health OB/GYN practice locations across the system. This marks the first time UNG Health OB/GYNs can offer FemVue evaluation and FemaSeed as first-line treatment options.

Why it matters — FEMY watchers would care because this partnership expands the commercial availability of the company's fertility products within a leading academic health system's OB/GYN practices, advancing Femasys' initiative to bring fertility evaluation and treatment earlier into the care pathway.

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

Benzinga · 19 Aug 2026positive

The U.S. Food and Drug Administration authorized the modular premarket approval application pathway for FemBloc, Femasys' non-surgical permanent birth control technology. This represents a regulatory milestone for the device.

Why it matters — For FEMY watchers, this establishes a clearer regulatory route for FemBloc, potentially advancing its path toward FDA approval.

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

GlobeNewsWire · 14 Aug 2026positive

Femasys reported financial results for the second quarter ended June 30, 2026 and provided a corporate update, highlighting that $30 million in financing will support the U.S. commercial strategy for its FemaSeed fertility portfolio and advancement of its FemBloc clinical and regulatory program toward U.S. approval.

Why it matters — FEMY watchers would care because the financing and stated progress on both the FemaSeed commercial strategy and FemBloc regulatory pathway signal continued execution toward key U.S. milestones for the company's core product portfolio.

FAQ

Frequently asked questions about FEMY stock

What is the FEMY stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Femasys, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FEMY stock a buy right now?

Of the 3 analysts covering Femasys, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Femasys, Inc. 43 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FEMY?

As at 19 Sept 2026, Femasys, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will FEMY stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +286.1% from the last close, and Ticker Nerd's factor model ranks Femasys, Inc. 43 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FEMY stock forecast for 2030?

No analyst covering Femasys, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FEMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $23 over the next 12 months.

How has FEMY stock performed over the past year?

Femasys, Inc. returned -64.0% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Femasys, Inc. do?

Femasys Inc. is a biomedical company focused on women’s reproductive health.

What is the latest news on FEMY?

The most recent item we track (GlobeNewsWire, 15 Sept 2026): "Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's Care". Femasys announced that Minnesota Women's Care will adopt its FemaSeed Complete portfolio and FemVue technology for fertility diagnostic evaluation and in-office first-line fertility treatment across its four OB/GYN practice locations. This marks an advancement in the company's expansion within the OB/GYN market.

Company

About Femasys, Inc.

Femasys Inc. is a biomedical company focused on women’s reproductive health. The company develops and commercializes accessible, minimally invasive, in-office therapeutic and diagnostic products designed to address unmet needs in fertility care, birth control, and gynecologic testing. Its portfolio includes FemVue for fallopian tube assessment, FemCath for selective tube evaluation, FemCerv for endocervical tissue sampling, FemBloc for non-surgical permanent birth control, and FemaSeed for assisted insemination. Femasys also offers related products and technologies used by physicians and women’s healthcare providers in office-based settings. Headquartered in Suwanee, Georgia, Femasys serves both U.S. and international markets with a focus on improving reproductive healthcare delivery.

CEO Ms. Kathy Lee-Sepsick M.B.A. · 51 employees · United States · https://femasys.com